Ontology type: schema:ScholarlyArticle
2013-01
AUTHORSK. N. Chi, A. Tolcher, P. Lee, P. J. Rosen, C. K. Kollmannsberger, K. P. Papadopoulos, A. Patnaik, A. Molina, J. Jiao, C. Pankras, B. Kaiser, A. Bernard, N. Tran, M. Acharya
ABSTRACTPURPOSE: To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Men with progressive metastatic mCRPC who failed gonadotropin-releasing hormone therapy and ≥1 lines of chemotherapy were enrolled. Patients received two doses of dextromethorphan HBr-30 mg (n = 18; group A) or theophylline-100 mg (n = 16; group B) under fasting conditions; one dose on cycle 1, day -8, and the other dose on cycle 1, day 8. Only patients with extensive CYP2D6 metabolizing status were assigned to group A. All patients received continuous daily oral abiraterone acetate (1,000 mg) plus prednisone (10 mg) starting on cycle 1, day 1. RESULTS: Coadministration of abiraterone acetate plus prednisone increased the systemic exposure of dextromethorphan by approximately 100%. Ratios of geometric means for maximum plasma concentration (C(max)) (275.36%) and area under plasma concentration-time curves from time 0 to 24 h (AUC(24h)) (268.14%) of dextromethorphan were outside the bioequivalence limit. The pharmacokinetics of theophylline was unaltered following coadministration of abiraterone acetate plus prednisone. Ratios of geometric means [C(max); 102.36% and AUC(24h); 108.03%] of theophylline exposure parameters were within the bioequivalence limit. The safety profile of abiraterone acetate was consistent with reported toxicities. CONCLUSION: Abiraterone acetate plus prednisone increased the exposure of dextromethorphan, suggesting a need for caution when coadministrating with known CYP2D6 substrates. The pharmacokinetics of theophylline was unaffected when coadministered with abiraterone acetate plus prednisone. More... »
PAGES237-244
http://scigraph.springernature.com/pub.10.1007/s00280-012-2001-0
DOIhttp://dx.doi.org/10.1007/s00280-012-2001-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1022092108
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/23064959
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Public Health and Health Services",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Abiraterone Acetate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Androstadienes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Area Under Curve",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cytochrome P-450 CYP1A2",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cytochrome P-450 CYP2D6",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Dextromethorphan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Interactions",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Metastasis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prednisone",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prostatic Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Theophylline",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, 600 West 10th Avenue, V5Z4E6, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Chi",
"givenName": "K. N.",
"id": "sg:person.01142252161.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "South Texas Accelerated Research Therapeutics",
"id": "https://www.grid.ac/institutes/grid.477989.c",
"name": [
"South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, TX, USA"
],
"type": "Organization"
},
"familyName": "Tolcher",
"givenName": "A.",
"id": "sg:person.013317163017.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013317163017.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Tower Cancer Research Foundation",
"id": "https://www.grid.ac/institutes/grid.478023.a",
"name": [
"Tower Cancer Research Foundation, Beverly Hills, CA, USA"
],
"type": "Organization"
},
"familyName": "Lee",
"givenName": "P.",
"id": "sg:person.01022031333.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022031333.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Providence Saint Joseph Medical Center",
"id": "https://www.grid.ac/institutes/grid.490448.5",
"name": [
"Providence Saint Joseph Medical Center, Burbank, CA, USA"
],
"type": "Organization"
},
"familyName": "Rosen",
"givenName": "P. J.",
"id": "sg:person.0724042407.50",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724042407.50"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, 600 West 10th Avenue, V5Z4E6, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Kollmannsberger",
"givenName": "C. K.",
"id": "sg:person.0660645031.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "South Texas Accelerated Research Therapeutics",
"id": "https://www.grid.ac/institutes/grid.477989.c",
"name": [
"South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, TX, USA"
],
"type": "Organization"
},
"familyName": "Papadopoulos",
"givenName": "K. P.",
"id": "sg:person.011133434022.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011133434022.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "South Texas Accelerated Research Therapeutics",
"id": "https://www.grid.ac/institutes/grid.477989.c",
"name": [
"South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, TX, USA"
],
"type": "Organization"
},
"familyName": "Patnaik",
"givenName": "A.",
"id": "sg:person.01036311176.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036311176.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "RAND Corporation",
"id": "https://www.grid.ac/institutes/grid.34474.30",
"name": [
"Janssen Research and Development LLC, Los Angeles, CA, USA"
],
"type": "Organization"
},
"familyName": "Molina",
"givenName": "A.",
"id": "sg:person.012576447577.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012576447577.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Janssen (United States)",
"id": "https://www.grid.ac/institutes/grid.497530.c",
"name": [
"Janssen Research and Development LLC, Raritan, NJ, USA"
],
"type": "Organization"
},
"familyName": "Jiao",
"givenName": "J.",
"id": "sg:person.01023060661.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023060661.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"British Columbia Cancer Agency, 600 West 10th Avenue, V5Z4E6, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Pankras",
"givenName": "C.",
"id": "sg:person.01205422461.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205422461.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "South Texas Accelerated Research Therapeutics",
"id": "https://www.grid.ac/institutes/grid.477989.c",
"name": [
"South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, TX, USA"
],
"type": "Organization"
},
"familyName": "Kaiser",
"givenName": "B.",
"id": "sg:person.01173433761.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173433761.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Janssen (United States)",
"id": "https://www.grid.ac/institutes/grid.497530.c",
"name": [
"Janssen Research and Development LLC, Raritan, NJ, USA"
],
"type": "Organization"
},
"familyName": "Bernard",
"givenName": "A.",
"id": "sg:person.0721703640.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721703640.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "RAND Corporation",
"id": "https://www.grid.ac/institutes/grid.34474.30",
"name": [
"Janssen Research and Development LLC, Los Angeles, CA, USA"
],
"type": "Organization"
},
"familyName": "Tran",
"givenName": "N.",
"id": "sg:person.01253535661.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253535661.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Janssen (United States)",
"id": "https://www.grid.ac/institutes/grid.497530.c",
"name": [
"Janssen Research and Development LLC, Raritan, NJ, USA"
],
"type": "Organization"
},
"familyName": "Acharya",
"givenName": "M.",
"id": "sg:person.01253457116.57",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253457116.57"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0140-6736(10)61389-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005976220"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2008.20.0642",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011914597"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1111/j.1365-2710.2007.00815.x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012333988"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2009.24.1281",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013861469"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/0008-5472.can-08-0249",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017269047"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1014618",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018044872"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2009.25.9259",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026303880"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1046/j.1365-2125.1998.00719.x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027361200"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1046/j.1365-2125.1998.00719.x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027361200"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa041318",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028543233"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa040720",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029249997"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2007.12.4487",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031178629"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00002512-200320100-00005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031740200",
"https://doi.org/10.2165/00002512-200320100-00005"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00002512-200320100-00005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031740200",
"https://doi.org/10.2165/00002512-200320100-00005"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2009.24.6819",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033684430"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdq050",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037456851"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.bjc.6601879",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037763577",
"https://doi.org/10.1038/sj.bjc.6601879"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.bjc.6601879",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037763577",
"https://doi.org/10.1038/sj.bjc.6601879"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-11-0815",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038628088"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/0008-5472.can-07-5997",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051493123"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdl498",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051931730"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3322/ca.2007.0010",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052065817"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm950749y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055957296"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm950749y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055957296"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00008571-199204000-00004",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1060289224"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00008571-199204000-00004",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1060289224"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1097/00008571-199204000-00004",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1060289224"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.2174/0929867054367185",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1069160512"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1079893102",
"type": "CreativeWork"
}
],
"datePublished": "2013-01",
"datePublishedReg": "2013-01-01",
"description": "PURPOSE: To assess the effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan HBr (CYP2D6 substrate) and theophylline (CYP1A2 substrate) in patients with metastatic castration-resistant prostate cancer (mCRPC).\nMETHODS: Men with progressive metastatic mCRPC who failed gonadotropin-releasing hormone therapy and \u22651 lines of chemotherapy were enrolled. Patients received two doses of dextromethorphan HBr-30 mg (n = 18; group A) or theophylline-100 mg (n = 16; group B) under fasting conditions; one dose on cycle 1, day -8, and the other dose on cycle 1, day 8. Only patients with extensive CYP2D6 metabolizing status were assigned to group A. All patients received continuous daily oral abiraterone acetate (1,000 mg) plus prednisone (10 mg) starting on cycle 1, day 1.\nRESULTS: Coadministration of abiraterone acetate plus prednisone increased the systemic exposure of dextromethorphan by approximately 100%. Ratios of geometric means for maximum plasma concentration (C(max)) (275.36%) and area under plasma concentration-time curves from time 0 to 24 h (AUC(24h)) (268.14%) of dextromethorphan were outside the bioequivalence limit. The pharmacokinetics of theophylline was unaltered following coadministration of abiraterone acetate plus prednisone. Ratios of geometric means [C(max); 102.36% and AUC(24h); 108.03%] of theophylline exposure parameters were within the bioequivalence limit. The safety profile of abiraterone acetate was consistent with reported toxicities.\nCONCLUSION: Abiraterone acetate plus prednisone increased the exposure of dextromethorphan, suggesting a need for caution when coadministrating with known CYP2D6 substrates. The pharmacokinetics of theophylline was unaffected when coadministered with abiraterone acetate plus prednisone.",
"genre": "research_article",
"id": "sg:pub.10.1007/s00280-012-2001-0",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1088364",
"issn": [
"0344-5704",
"1432-0843"
],
"name": "Cancer Chemotherapy and Pharmacology",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "71"
}
],
"name": "Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer",
"pagination": "237-244",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"694070b75dea6cefc8c358b315f9057b6ff3ea4dcd1c56132bbe60d20243e703"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"23064959"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"7806519"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00280-012-2001-0"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1022092108"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00280-012-2001-0",
"https://app.dimensions.ai/details/publication/pub.1022092108"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T18:20",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000512.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1007%2Fs00280-012-2001-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-2001-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-2001-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-2001-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-2001-0'
This table displays all metadata directly associated to this object as RDF triples.
305 TRIPLES
21 PREDICATES
67 URIs
36 LITERALS
24 BLANK NODES